Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$4.46 USD
+0.15 (3.48%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.46 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Aquestive Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -7.87 | -54.41 | -70.54 | -55.78 | -66.25 |
Depreciation/Amortization & Depletion | 3.32 | 2.60 | 6.70 | 6.03 | 4.83 |
Net Change from Assets/Liabilities | -5.34 | 32.01 | -1.73 | -4.41 | -11.12 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 3.51 | 10.01 | 32.60 | 8.71 | 12.33 |
Net Cash From Operating Activities | -6.38 | -9.79 | -32.98 | -45.46 | -60.21 |
Property & Equipment | -1.00 | -1.02 | -0.91 | -0.52 | -0.66 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | -1.50 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -1.00 | -2.52 | -0.91 | -0.52 | -0.66 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 17.26 | 13.59 | 30.12 | 6.22 | 39.32 |
Issuance (Repayment) of Debt | -22.49 | -2.03 | 0.00 | -24.75 | 17.06 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 9.20 | 0.00 | -0.01 | 46.99 | -6.77 |
Net Cash from Financing Activities | 3.97 | 11.56 | 30.11 | 28.46 | 49.60 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -3.40 | -0.75 | -3.78 | -17.52 | -11.27 |
Cash at Beginning of Period | 27.27 | 28.02 | 31.81 | 49.33 | 60.60 |
Cash at End of Period | 23.87 | 27.27 | 28.02 | 31.81 | 49.33 |
Diluted Net EPS | -0.13 | -1.12 | -1.85 | -1.66 | -2.61 |
Fiscal Year End for Aquestive Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -15.57 | -12.83 | -7.87 | 0.24 | 2.28 |
Depreciation/Amortization & Depletion | 5.75 | 2.88 | 3.32 | 1.05 | 0.73 |
Net Change from Assets/Liabilities | -10.41 | -2.05 | -5.34 | -4.24 | -2.80 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.84 | 1.61 | 3.51 | 1.51 | 0.71 |
Net Cash From Operating Activities | -17.39 | -10.38 | -6.38 | -1.44 | 0.91 |
Property & Equipment | -0.06 | -0.03 | -1.00 | -0.98 | -0.83 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.06 | -0.03 | -1.00 | -0.98 | -0.83 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 84.36 | 82.64 | 17.26 | 13.65 | 8.66 |
Issuance (Repayment) of Debt | -0.01 | -0.01 | -22.49 | -13.58 | -13.57 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.90 | -0.89 | 9.20 | -0.01 | -0.01 |
Net Cash from Financing Activities | 83.45 | 81.74 | 3.97 | 0.06 | -4.92 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 66.00 | 71.33 | -3.40 | -2.36 | -4.84 |
Cash at Beginning of Period | 23.87 | 23.87 | 27.27 | 27.27 | 27.27 |
Cash at End of Period | 89.87 | 95.20 | 23.87 | 24.92 | 22.44 |
Diluted Net EPS | -0.03 | -0.17 | -0.11 | -0.03 | -0.10 |